TherapeuticsMD Announces Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
TherapeuticsMD (TXMD) Misses Q2 EPS by 6c, Revenues Beat; Raises Q3 & FY19 Revenue Guidance
August 6, 2019 5:21 PM EDTTherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.23), $0.06 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $6 million versus the consensus estimate of $5.12 million.
MVEXXY® Net Revenue $3.1 Million for the Second Quarter of 2019Total Net Revenue for the Second Quarter of 2019 Above... More